SCHEMBL12561725

SCHEMBL12561725

Fc1ccc(-c2nc(-c3ccc4[nH]ccc4c3)[nH]c2-c2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 11/20 0.62
MAPK13 O15264 7/20 0.62
MAPK12 P53778 7/20 0.62
MAPK11 Q15759 7/20 0.62
GCGR P47871 5/20 0.62
ALOX5 P09917 4/20 0.62
EGFR P00533 1/20 0.54
NPC1 O15118 1/20 0.54
CSNK1D P48730 2/20 0.53
PRKD3 O94806 1/20 0.53
MAP4K4 O95819 1/20 0.53
FRK P42685 1/20 0.53
MAPK9 P45984 1/20 0.53
CSNK1A1 P48729 1/20 0.53
GSK3B P49841 1/20 0.53
PTK6 Q13882 1/20 0.53
PRKD2 Q9BZL6 1/20 0.53
CLK4 Q9HAZ1 1/20 0.53
PTPN1 P18031 1/20 0.53
KDM4E B2RXH2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16292225 0.83 MAPK13 (0.85) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL1629037 0.83 MAPK13 (0.85) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL85099 0.82 MAPK13 (0.68) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL12858561 0.79 MAPK13 (0.65) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL5759775 0.79 MAPK14 (0.61) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL4552316 0.77 MAPK14 (1.00) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL29884681 0.77 MAPK14 (0.64) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL9195042 0.77 MAPK14 (1.00) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL29642917 0.76 PTPN1 (0.66) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL7159987 0.76 PTPN1 (0.66) MAPK14MAPK13MAPK12MAPK11GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150374669-A1 ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS LORUS THERAPEUTICS INC. (CA) 2015-12-31 US disclosed
US-20150374669-A1 ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS LORUS THERAPEUTICS INC. (CA) 2015-12-31 US disclosed
US-8987305-B2 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents APTOSE BIOSCIENCES INC. (CA) 2015-03-24 US disclosed
US-8987305-B2 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents APTOSE BIOSCIENCES INC. (CA) 2015-03-24 US disclosed
US-8969372-B2 Aryl imidazoles and their use as anti-cancer agents Aptose Boisciences Inc. (CA) 2015-03-03 US disclosed
US-8969372-B2 Aryl imidazoles and their use as anti-cancer agents Aptose Boisciences Inc. (CA) 2015-03-03 US disclosed
US-20130177632-A1 2,4,5-TRISUBSTITUTED IMIDAZOLES AND THEIR USE AS ANTI-MICROBIAL AGENTS APTOSE BIOSCIENCES INC. (CA) 2013-07-11 US disclosed
US-20130177632-A1 2,4,5-TRISUBSTITUTED IMIDAZOLES AND THEIR USE AS ANTI-MICROBIAL AGENTS APTOSE BIOSCIENCES INC. (CA) 2013-07-11 US disclosed
US-8394815-B2 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents LORUS THERAPEUTICS INC. (CA) 2013-03-12 US disclosed
US-8394815-B2 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents LORUS THERAPEUTICS INC. (CA) 2013-03-12 US disclosed
US-20110152337-A1 2,4,5-TRISUBSTITUTED IMIDAZOLES AND THEIR USE AS ANTI-MICROBIAL AGENTS LORUS THERAPEUTICS INC. (CA) 2011-06-23 US disclosed
US-20110152337-A1 2,4,5-TRISUBSTITUTED IMIDAZOLES AND THEIR USE AS ANTI-MICROBIAL AGENTS LORUS THERAPEUTICS INC. (CA) 2011-06-23 US disclosed
US-7884120-B2 microbiocides such as 2-(2-methyl-1H-indol-3-yl)-3a,11b-dihydro-1H-phenanthro[9,10-d]imidazole; bactericides; fungicides LORUS THERAPEUTICS INC. (CA) 2011-02-08 US disclosed
US-7884120-B2 microbiocides such as 2-(2-methyl-1H-indol-3-yl)-3a,11b-dihydro-1H-phenanthro[9,10-d]imidazole; bactericides; fungicides LORUS THERAPEUTICS INC. (CA) 2011-02-08 US disclosed
US-20080262015-A9 Aryl imidazoles and their use as anti-cancer agents LORUS THERAPEUTICS INC. (CA) 2008-10-23 US disclosed
US-20080262015-A9 Aryl imidazoles and their use as anti-cancer agents LORUS THERAPEUTICS INC. (CA) 2008-10-23 US disclosed
US-20070123553-A1 Aryl imidazoles and their use as anti-cancer agents LORUS THERAPEUTICS INC. (CA) 2007-05-31 US disclosed
US-20070123553-A1 Aryl imidazoles and their use as anti-cancer agents LORUS THERAPEUTICS INC. (CA) 2007-05-31 US disclosed
US-20070105929-A1 2, 4, 5 - Trisubstituted Imidazoles And Their Use As Anti-Microbial Agents APTOSE BIOSCIENCES INC. (CA) 2007-05-10 US disclosed
US-20070105929-A1 2, 4, 5 - Trisubstituted Imidazoles And Their Use As Anti-Microbial Agents APTOSE BIOSCIENCES INC. (CA) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130177632-A1 2,4,5-TRISUBSTITUTED IMIDAZOLES AND THEIR USE AS ANTI-MICROBIAL AGENTS IDO2, ERG28, IL4 MAPK14 2550/4885MAPK13 3668/4885MAPK12 3161/4885
US-20110152337-A1 2,4,5-TRISUBSTITUTED IMIDAZOLES AND THEIR USE AS ANTI-MICROBIAL AGENTS IDO2, ERG28, IL4 MAPK14 2550/4885MAPK13 3668/4885MAPK12 3161/4885
US-20070123553-A1 Aryl imidazoles and their use as anti-cancer agents AHR, AADAC, CBR3 MAPK14 3469/4885MAPK13 4059/4885MAPK12 3204/4885
US-20150374669-A1 ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS AHR, CBR3, AADAC MAPK14 3647/4885MAPK13 4087/4885MAPK12 3446/4885
US-20070105929-A1 2, 4, 5 - Trisubstituted Imidazoles And Their Use As Anti-Microbial Agents IDO2, ERG28, IL4 MAPK14 2550/4885MAPK13 3668/4885MAPK12 3161/4885
US-20080262015-A9 Aryl imidazoles and their use as anti-cancer agents AHR, AADAC, CBR3 MAPK14 3469/4885MAPK13 4059/4885MAPK12 3204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.